Management of dyslipidaemia in patients with comorbidities-facing the challenge: type 1 diabetes mellitus

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Type 1 diabetes is linked to higher cardiovascular risk, unlike type 2 diabetes.
• Age and sex are key predictors of cardiovascular risk in type 1 diabetes, but low-density lipoprotein cholesterol (LDL-C) and lipid-lowering therapy roles are less defined.
• Existing clinical trial data on lipid-lowering treatments primarily involves type 2 diabetes patients, limiting specific insights for type 1 diabetes.

Purpose of the Study:

• To review the evidence on lipid-lowering drug classes for cardiovascular risk reduction in patients with type 1 diabetes.
• To address the gap in understanding lipid-lowering therapy efficacy and safety specifically for type 1 diabetes.
• To synthesize real-world findings and limited trial data relevant to type 1 diabetes cardiovascular outcomes.

Main Methods:

• Literature review of studies focusing on lipid-lowering therapies in type 1 diabetes.
• Analysis of available randomized clinical trial data, acknowledging its predominant focus on type 2 diabetes.
• Synthesis of real-world evidence pertaining to cardiovascular risk in type 1 diabetes patients undergoing lipid management.

Main Results:

• Limited direct evidence from randomized trials on lipid-lowering therapies in type 1 diabetes.
• Cardiovascular risk in type 1 diabetes is influenced by factors like age at onset and sex.
• Real-world data provides crucial insights into lipid management and outcomes in type 1 diabetes.

Conclusions:

• Further research is needed to establish clear guidelines for lipid-lowering therapies in type 1 diabetes.
• Current evidence predominantly stems from type 2 diabetes studies, necessitating cautious extrapolation.
• Understanding the specific cardiovascular risk factors and treatment responses in type 1 diabetes is critical for effective management.